Prilenia Archieves Last Patient Visit in Phase 3 PROOF-HD Clinical Study for Huntington's Diseasekatie8288Mar 28, 20230 min read
Prilenia has entered into a collaboration and license agreement with Ferrer for the commercialization and co-development of pridopidine in Europe and other select markets
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
Comments